James Yan, Ph.D., joined Zai Lab in September 2015 and currently serves as Chief Operating Officer, Global R&D.
Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries.
Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a member of Committee of Drug Toxicology and Safety Evaluation, CST and a member of Committee of Biotechnology Pharmaceutical Toxicology and Safety Evaluation, CST , a member of Pharmaceutical Toxicology Committee of China Pharmacology Society, a member of Pharmaceutical Toxicology Committee of Shanghai Pharmacology Society, and a member of Pharmaceutical Digitization and Innovative Therapy Committee of China PhIRDA, vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA), a standing director of China Biopharmaceutical Industry Innovation and Transformation Alliance (CBIITA), vice chairman of Oncology Medicine Committee of CBIITA, and vice chairman of Yangtze River Delta Pharmaceutical Innovation and Development Alliance (YPIDA).
